HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NACDS Marketplace In Brief

This article was originally published in The Tan Sheet

Executive Summary

Dr. Reddy's readies OTC omeprazole launch: Dr. Reddy's prepares to launch its omeprazole 20.6 mg OTC proton pump inhibitor, the equivalent to AstraZeneca's Prilosec OTC, by the end of July. Milan Kalawadia, associate director of the Hyderabad, India-based firm's North American investor relations, did not comment on which retailers will carry the product, but said it will sell in 14-, 28- and 42-count blister packs, the same as the branded product. At the National Association of Chain Drug Stores Marketplace trade show in Boston June 30, Dr. Reddy's senior director of OTC marketing, John Segura, said the firm is "looking forward to" the launch after getting "both FDA approval and the resolution of a lawsuit" to get there. FDA approved Dr. Reddy's abbreviated new drug application June 5 and a court ruled against AstraZeneca's patent-infringement challenge to Dr. Reddy's private-label product (1"The Tan Sheet" March 23, 2009). A final decision is pending on AstraZeneca's appeal of the ruling, but Dr. Reddy's plans to launch the product. "While any launch prior to a final decision is technically at risk, we are confident that we do not infringe any patents asserted against us," Kalawadia said
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

RS136391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel